Hunan Er-Kang Pharmaceutical Co., Ltd
Shenzhen Stock Exchange 300267.SZ
Hunan Er-Kang Pharmaceutical Co., Ltd Interest Coverage Ratio for the year ending December 31, 2023: -28.85
-
Hunan Er-Kang Pharmaceutical Co., Ltd Interest Coverage Ratio for the year ending December 31, 2022 was 5.78, a 106.50% change year over year.
-
Hunan Er-Kang Pharmaceutical Co., Ltd Interest Coverage Ratio for the year ending December 31, 2021 was -88.84, a -593.95% change year over year.
-
Hunan Er-Kang Pharmaceutical Co., Ltd Interest Coverage Ratio for the year ending December 31, 2020 was 17.99, a -70.20% change year over year.
-
Hunan Er-Kang Pharmaceutical Co., Ltd Interest Coverage Ratio for the year ending December 31, 2019 was 60.34, a -73.57% change year over year.
| Date | Interest Coverage Ratio | Debt to Equity Ratio | Interest Expense To Sales | Inventory Turnover Ratio |
|---|
Don’t Miss A Beat
| CEO | Mr. Qingrong Sun |
| IPO Date | Sept. 27, 2011 |
| Location | China |
| Headquarters | Liuyang National Eco & Technical Dev Zn |
| Employees | 1,497 |
| Sector | Healthcare |
| Industries | |
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. The company was founded in 2003 and is based in Liuyang, China.
Past 5 years
StockViz Staff
February 3, 2025
Any question? Send us an email